Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
16.46
-0.17 (-1.02%)
At close: Feb 21, 2025, 4:00 PM
16.57
+0.11 (0.67%)
After-hours: Feb 21, 2025, 4:00 PM EST
Fulgent Genetics Revenue
Fulgent Genetics had revenue of $71.74M in the quarter ending September 30, 2024, a decrease of -15.28%. This brings the company's revenue in the last twelve months to $277.76M, down -3.02% year-over-year. In the year 2023, Fulgent Genetics had annual revenue of $289.21M, down -53.27%.
Revenue (ttm)
$277.76M
Revenue Growth
-3.02%
P/S Ratio
1.78
Revenue / Employee
$234,595
Employees
1,184
Market Cap
503.46M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 289.21M | -329.76M | -53.27% |
Dec 31, 2022 | 618.97M | -373.62M | -37.64% |
Dec 31, 2021 | 992.58M | 570.87M | 135.37% |
Dec 31, 2020 | 421.71M | 389.18M | 1,196.46% |
Dec 31, 2019 | 32.53M | 11.18M | 52.35% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
FLGT News
- 16 days ago - Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025 - Business Wire
- 18 days ago - Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics - Business Wire
- 2 months ago - Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside - Seeking Alpha
- 3 months ago - Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Fulgent Reports Third Quarter 2024 Financial Results - Business Wire
- 3 months ago - Fulgent to Participate in Upcoming Conferences - Business Wire
- 4 months ago - Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1 - Business Wire
- 4 months ago - Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024 - Business Wire